Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

2015

Purpose To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

17

References

102

Citations